MARKET

EVFM

EVFM

Evofem Bioscienc
OTCMQB
0.016
-0.001
-3.03%
Closed 15:44 04/12 EDT
OPEN
0.017
PREV CLOSE
0.017
HIGH
0.017
LOW
0.015
VOLUME
810.80K
TURNOVER
12.43K
52 WEEK HIGH
196.25
52 WEEK LOW
0.015
MARKET CAP
735.03K
P/E (TTM)
0.299
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at EVFM last week (0401-0405)?
Weekly Report · 5d ago
Weekly Report: what happened at EVFM last week (0325-0329)?
Weekly Report · 04/01 10:52
Evofem Biosciences Issues Update with Latest Presentation
TipRanks · 03/28 21:22
EVFM Stock Earnings: Evofem Biosciences Reported Results for Q4 2023
Evofem Biosciences reported earnings per share of -44 cents. The company reported revenue of $4.84 million. The stock was down 2.7% to $2.05 in the after-hours trading session on Tuesday.  
Investorplace · 03/27 17:52
*Evofem Biosciences 4Q Sales $4.8M >EVFM
Dow Jones · 03/27 12:37
*Evofem Biosciences 4Q Loss/Shr 44c >EVFM
Dow Jones · 03/27 12:36
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
Evofem Biosciences, Inc. Announces financial results for the fourth quarter and year ended December 31, 2023. Third Consecutive Year of Phexxi Net Sales Growth. Total Operating Expense Reduced 64% from 2022 Levels. Entered into a definitive agreement to be acquired by Aditxt, Inc., in 2024.
PR Newswire · 03/27 12:36
Weekly Report: what happened at EVFM last week (0318-0322)?
Weekly Report · 03/25 10:54
More
About EVFM
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. It is engaged in developing and commercializing products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). Its product, Phexxi vaginal gel, is a hormone-free, woman-controlled, on-demand prescription contraceptive gel for women. Its lead clinical program is evaluating Phexxi (using the investigational name EVO100) for the prevention of chlamydia and gonorrhea in women. EVO200 vaginal gel (EVO200), its investigational candidate for the reduction of recurrent bacterial vaginosis (BV), uses the same vaginal potential of hydrogen (pH) modulator platform as Phexxi. It also focuses on developing Multipurpose Prevention Technology (MPT) vaginal gel for indications, including the prevention of human immunodeficiency virus (HIV) in women through Orion Biotechnology Canada Ltd.

Webull offers Evofem Biosciences Inc stock information, including OTCMQB: EVFM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EVFM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EVFM stock methods without spending real money on the virtual paper trading platform.